2018
The Complexities of Evaluating the Exposome in Psychiatry: A Data-Driven Illustration of Challenges and Some Propositions for Amendments
Guloksuz S, Rutten B, Pries L, Have M, de Graaf R, van Dorsselaer S, Klingenberg B, van Os J, Ioannidis J, Group T. The Complexities of Evaluating the Exposome in Psychiatry: A Data-Driven Illustration of Challenges and Some Propositions for Amendments. Schizophrenia Bulletin 2018, 44: 1175-1179. PMID: 30169883, PMCID: PMC6192470, DOI: 10.1093/schbul/sby118.Peer-Reviewed Original ResearchMeSH KeywordsBiomedical ResearchClinical ProtocolsData Interpretation, StatisticalHealth SurveysHumansMental DisordersNetherlandsPsychiatryConceptsMental health outcomesHealth outcomesNetherlands Mental Health SurveyMental Health SurveyPre-specified analysis planFalsification endpointsModifiable factorsSources of heterogeneityHealth SurveyIntervention effectsSelective reportingAnalysis planP-valueOutcomesEffect sizeVibration of effectsAnalytical planSame outcomeDifferent studiesExploratory analysisExposureStudy 2 dataP-value threshold
2013
Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trial
Tek C, Guloksuz S, Srihari VH, Reutenauer EL. Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trial. BMC Psychiatry 2013, 13: 176. PMID: 23805859, PMCID: PMC3702521, DOI: 10.1186/1471-244x-13-176.Peer-Reviewed Original ResearchConceptsSevere mental illnessEfficacy of naltrexoneWeight gainOutcome measurementsHealth problemsMental illnessGreater New Haven areaTumor necrosis factor alphaWeight lossCurrent available medicationsPlacebo-controlled trialHigh-sensitivity CRPOpioid receptor antagonistSecondary outcome measuresSerum lipid profilePrimary outcome measurementBody mass indexD2 receptor blockadeEffects of naltrexoneNovel pharmacological optionsNecrosis factor alphaDoses of naltrexoneMajor health problemRates of obesitySignificant weight loss